Business FYR 2025
Category: dates
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
Transgene Announces Financial Calendar for 2026
financial calendar 2026
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero
SAB Jan26
Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
C. Ottensmeier, et al. medRxiv Preprint available on medRxiv website – Download the Article
Nature Communications
TG4050 TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings Article available for the first time on Nature Communications website – Download the Article
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
medRxiv 2026
Transgene to Participate in Upcoming Investor Meetings
investors 2026
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
resume 2025
Transgene Announces the Success of Its Capital Increase
Results 2025